VCEL
NASDAQ HealthcareVericel Corporation - Common Stock
Biotechnology
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
๐ Market Data
| Price | $43.59 |
|---|---|
| Volume | 250,743 |
| Market Cap | 2.23B |
| Beta | 1.070 |
| RSI (14-Day) | 30.7 |
| 200-Day MA | $37.89 |
| 50-Day MA | $43.89 |
| 52-Week High | $49.32 |
| 52-Week Low | $28.95 |
| P/E Ratio | 90.81 |
| Forward P/E | 51.52 |
| Price / Book | 6.03 |
๐ฏ Investment Strategy Scores
VCEL scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (80/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (9/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find VCEL in your text
Paste any article, transcript, or post โ the tool will extract VCEL and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.